Abstracts tagged "Abatacept and rheumatoid arthritis (RA)"

Abstract Number: 2490 • 2014 ACR/ARHP Annual Meeting
Assessment of Structural Benefits of SC Abatacept Using MRI in Patients with RA Who Have Failed 1 or 2 TNFs and Correlated with Clinical Outcomes As Measured By DAS28(ESR)
Norman B. Gaylis¹, Steven Needell² and Joanne Sagliani³, ¹Arthritis & Rheumatic Disease Specialties, Aventura, FL, ²Boca Radiology, Boca Raton, FL, ³Research, Arthritis & Rheumatic Disease Specialties, Aventura, FL
Background/Purpose: Previous studies1-2 suggest the structural benefit of IV abatacept in patients with RA who have previously failed MTX, TNF therapy or both. Objectives:This study…
Abstract Number: 1517 • 2014 ACR/ARHP Annual Meeting
Analysis of Gene Expression Fluctuation with Abatacept Highlights the Involvement of the Proteasome Pathway As a Mechanism of Action of Abatacept in Rheumatoid Arthritis
C Derambure¹, O Vittecoq^1,2, G Dzangue Tchoupou¹, Maria-Antonietta d'Agostino³, P Gaudin⁴, C Gaillez⁵, M Le Bars⁶ and T Lequerré^1,2, ¹Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ²Department of Rheumatology, Rouen University Hospital, Rouen, France, ³AP-HP Ambroise Paré Hospital, Boulogne-Billancourt, France, ⁴Department of Rheumatology, University Hospital Grenoble, Grenoble, France, ⁵Formerly of Bristol-Myers Squibb, Rueil-Malmaison, France, ⁶Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: Abatacept (ABA) is a biologic therapy targeting T cells, which play a major role in the pathophysiology of RA. Overall, 57.1% of patients reached…
Abstract Number: 1485 • 2013 ACR/ARHP Annual Meeting
RNA Transcripts From Peripheral Blood Mononuclear Cells As Predictors Of Clinical Responsiveness In Rheumatoid Arthritis Subjects Treated With Abatacept
Matthew Henkel¹, Fang Du², Donald M. Jones³, Erich R Wilkerson², William Horne⁴, Jay K. Kolls⁵, Marc C. Levesque⁶ and Mandy McGeachy¹, ¹Medicine, Univeristy of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Pediatrics, University of Pittsburgh, Pittsburgh, PA, ⁵Richard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA
Background/Purpose: Biologics, including abatacept (CTLA4Ig), improve outcomes for many RA patients. However, approximately 40-50% of RA patients fail to respond to abatacept, and there are…
Abstract Number: 1421 • 2013 ACR/ARHP Annual Meeting
Treatment Responses and Their Predictors Of Abatacept In Biologic naïve Patients With Rheumatoid Arthritis; Data Form Abroad Study
Yutaka Kawahito¹, Takao Fujii², Akira Yokota³, Hideo Hashimoto⁴, Kiyoshi Matsui⁵, Kenji Miki⁶, Masayasu Kitano⁵, Naoki Shinmyo⁷, Aihiro Yamamoto¹, Koichiro Ohmura⁸, Takanori Kuroiwa⁹, Toshihiko Hidaka¹⁰, Ichiro Yoshii¹¹, Hideko Nakahara¹², Takashi Fujimoto¹³, Kosaku Murakami¹⁴, Satoshi Morita¹⁵, Masahiro Sekiguchi⁵, Norihiro Nishimoto^16,17, Tsuneyo Mimori⁸ and Hajime Sano⁵, ¹Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ²Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Yokota Clinic for Rheumatology, Osaka, Japan, ⁴Dept of Orthopedic Surgery, Rinku Hashimoto Rheumatology Orthopaedics, Osaka, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya-city, Japan, ⁶Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, ⁷Kashiba Asahigaoka Hospital, Kashiba, Japan, ⁸Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁹Department of Rheumatology, Yukioka Hospital, Osaka, Japan, ¹⁰Zenjinkai Shimin-No-Mori Hospital, Miyazaki, Japan, ¹¹Department of Orthopaedic Surgery, Yoshii Hospital, Shimanto, Japan, ¹²Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ¹³Nara Medical University, Kashihara, Japan, ¹⁴Rheumatology and Clinical Immunology, Osaka Red Cross Hospital, Osaka, Japan, ¹⁵Graduate School of Medicine & Medical Center, Department of Biostatistics and Epidemiology, Yokohama City University, Kanagawa, Japan, ¹⁶Tokyo Medical University, Tokyo, Japan, ¹⁷Osaka Rheumatology Clinic, Osaka, Japan
Background/Purpose: The identification of predictors of good response to biologic therapy is needed in the perspective of personalized medicine.　To determine the predicting factors of efficacy…
Abstract Number: 1415 • 2013 ACR/ARHP Annual Meeting
Safety and Effectiveness Of Abatacept In 3985 Japanese Patients With Rheumatoid Arthritis; Japan All-Cases Post-Marketing Surveillance
Takao Koike¹, Masayoshi Harigai², Naoki Ishiguro³, Shigeko Inokuma⁴, Junnosuke Ryu⁵, Syuji Takei⁶, Tsutomu Takeuchi⁷, Y. Tanaka⁸, Masahiko Watanabe⁹ and Hisashi Yamanaka¹⁰, ¹Rheumatology, NTT Sapporo Medical Center, Sapporo, Japan, ²Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Department of Allergy and Rheumatology diseases, Japanese Red Cross Medical Center, Tokyo, Japan, ⁵Nihon University School of Medicine, Tokyo, Japan, ⁶School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁸University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Bristol-Myers K.K, Tokyo, Japan, ¹⁰Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: A large-scale post-marketing surveillance (PMS) has been implemented to evaluate the safety and effectiveness on the use of intravenous abatacept (ABT) in Japanese patients…
Abstract Number: 430 • 2013 ACR/ARHP Annual Meeting
Comparing abatacept to Adalimumab, Etanercept and Infliximab As First Or Second Line Agents in Patients With Rheumatoid arthritis: Experience From the rhumadata® Clinical Database and Registry
Denis Choquette¹, Diane Sauvageau², Louis Bessette³, Boulos Haraoui^4,5, Jean Pierre Pelletier¹, Jean-Pierre Raynauld², Edith Villeneuve² and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ³Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ⁴Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁵Rhumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: The order of use of biologic agents is still a question for debate. Phase III trial data in MTX-IR patients show comparable efficacy results…
Abstract Number: 356 • 2012 ACR/ARHP Annual Meeting
Safety of Abatacept in Rheumatoid Arthritis with Chronic Hepatitis B VIRUS Infection
Melissa Padovan¹, Elisabetta Lanciano², Oscar Epis³, Alessandro Mathieu⁴, Giulia Erba⁵, Leopoldo Ciani⁶, Sarah Giacuzzo¹ and Marcello Govoni⁷, ¹Department if Clinical and Experimental Medicine, University of Ferrara, Section of Rheumatology, Ferrara, Italy, ²Section of Internal Medicine, Policlinico Universitario di Bari, Rheumatology Unit, Bari, Italy, ³Ospedale Niguarda Cà Granda, Rheumatology Unit, Milano, Italy, ⁴Medical Sciences, University of Cagliari, Rheumatology Unit, Cagliari, Italy, ⁵AO San Gerardo, Medical Clinics, Monza, Italy, ⁶Ospedale Civile di Legnano, Unit of Internal Medicine, Legnano, Italy, ⁷Department of Clinical and Experimental Medicine, Section of Rheumatology, Ferrara, Italy
Background/Purpose: In patients with rheumatoid arthritis (RA) concomitant hepatitis B (HBV) represents a therapeutic challenge limiting, DMARD treatment options (conventional and biologics, especially anti-TNFa and…
Abstract Number: 1289 • 2012 ACR/ARHP Annual Meeting
Abatacept Biologic-Free Remission Study in Established Rheumatoid Arthritis Patients. Orion Study
Tsutomu Takeuchi¹, Tsukasa Matsubara², Shuji Ohta³, Masaya Mukai⁴, Koichi Amano⁵, Shigeto Tohma⁶, Yoshiya Tanaka⁷, Hisashi Yamanaka⁸ and Nobuyuki Miyasaka⁹, ¹Keio University School of Medicine, Tokyo, Japan, ²Matsubara Mayflower Hospital, Hyogo, Japan, ³Department of Rheumatology, Taga General Hospital, Ibaraki, Japan, ⁴Dept Rheumatology & Hematology, Sapporo City General Hospital, Sapporo, Japan, ⁵Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ⁶Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ⁷The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁸Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁹Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Abatacept (ABA) has comparable efficacy to TNF inhibitors in achieving clinical remission in rheumatoid arthritis (RA) patients. However, although clinical evidence suggests that biologic-free…
Abstract Number: 2159 • 2012 ACR/ARHP Annual Meeting
Correlation of a Multi-Biomarker Disease Activity Response Assessment to Disease Activity Score 28 (C-Reactive Protein) Response Assessment and Omeract Ramris Scores in a Placebo-Controlled Rheumatoid Arthritis Clinical Trial with Abatacept (ASSET)
DJ Haney¹, G. Cavet², P. Durez³, R. Alten⁴, Gerd Burmester⁵, P. P. Tak⁶, Anca Catrina⁷, C. Gaillez⁸, M. Le Bars⁸, S. Connolly⁹ and R. Townsend⁹, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Crescendo Bioscience, Inc., South San Francisco, CA, ³Université Catholique de Louvain, Brussels, Belgium, ⁴Schlosspark-Klinik, University Medicine, Berlin, Germany, ⁵Charité-Universitätsmedizin, Berlin, Germany, ⁶Academic Medical Center/University of Amsterdam, Amsterdam, the Netherlands; GlaxoSmithKline, Stevenage, United Kingdom, ⁷Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁸Bristol-Myers Squibb, Rueil Malmaison, France, ⁹Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: A novel multi-biomarker disease activity (MBDA) score has been validated and is a tool for monitoring disease activity in RA.1 Here, we evaluate the…
Abstract Number: 2314 • 2012 ACR/ARHP Annual Meeting
Correlation Between Abatacept and Rheumatoid Factor – Can Rheumatoid Factor Be a Predictive Factor for Abatacept?
Tomonori Kobayakawa¹, Masatoshi Hayashi², Toshihisa Kanamono², Atsushi Kaneko³, Toshihisa Kojima⁴ and Naoki Ishiguro⁵, ¹Orthopedic Surgery, Nagoya university, Nagoya, Japan, ²Departments of Orthopedic surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ³Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya Univeristy, School of Medicine, Nagoya, Japan, ⁵Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan
Background/Purpose: Abatacept (ABT), a T-cell selective costimulatory regulator, went on the market in Japan in September 2010, with a number of reports issued on its…
Abstract Number: 2547 • 2012 ACR/ARHP Annual Meeting
Weekly Subcutaneous Abatacept Confers Comparable Onset of Treatment Response and Magnitude of Efficacy Improvement Over 6 Months When Administered with or without an Intravenous Abatacept Loading Dose
M. Schiff¹, R. Alten², M. Weinblatt³, P. Nash⁴, Roy Fleischmann⁵, P. Durez⁶, J. Kaine⁷, I. Delaet⁸, S. Kelly⁸, M. Maldonado⁸, S. Patel⁸ and M. C. Genovese⁹, ¹University of Colorado, Denver, CO, ²Schlosspark-Klinik, University Medicine, Berlin, Germany, ³Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ⁴University of Queensland, Brisbane, Australia, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶Université Catholique de Louvain, Brussels, Belgium, ⁷Sarasota Arthritis Research Center, Sarasota, FL, ⁸Bristol-Myers Squibb, Princeton, NJ, ⁹Stanford University, Palo Alto, CA
Background/Purpose: To compare clinical and functional responses with SC abatacept administered with or without an IV loading dose, in pts with active RA and inadequate…